Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.…
Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates
Genelux (NASDAQ: GNLX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 25 employees.
The shares were at 2.170 USD on 20 November 2026, down 60.0% over 52 weeks. Its 52-week range is 1.770 USD to 6.260 USD: the price is 65.3% below the high and 22.6% above the low.
Its market capitalisation is 103.36M USD.
Genelux reports return on equity of -278.5%.
It holds more cash than debt, a net cash position of 8.10M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.